•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences

Khaitan, Anderson Mori, Amarchand on $300m Indo-Jap Pharma sale

Khaitan & Co and Anderson, Mori & Tomotsune advised Japan’s Meiji Seika Pharma in buying Bangalore pharma company Medreich for Rs 1720 crore ($290m). Medreich was advised by Amarchand Mangaldas.

Khaitan corporate partner Bhavik Narsana, banking and finance partner Kumar Saurabh Singh, competition law partner Avaantika Kakkar, intellectual property partner Adheesh Nargolkar, real estate partner Abhishek Sharma and regulatory partner Sharad Vaid and Anderson Mori partners Yuichiro Nukada and Ryo Okochi acted for Meija.

Amarchand corporate partner Ashish Jejurkar and tax partner SR Patnaik acted for Medreich.

The buyout leads to the exit of the Singapore government’s investment arm Temasek which had invested Rs 109 crore in Medreich for a 25 per cent stake in 2005, reported Mint.

Amarchand, along with Luthra & Luthra, had also advised debt-ridden pharma giant Ranbaxy in being sold off to Sun Pharma two months ago.

Click to show 13 comments
at your own risk
By reading the comments you agree that they are the (often anonymous) personal views and opinions of readers, which may be biased and unreliable, and for which Legally India therefore has no liability. If you believe a comment is inappropriate, please click 'Report to LI' below the comment and we will review it as soon as practicable.